title: Urinary excretion of 19-noraldosterone, 18, 19-dihydroxycorticosterone and 18-hydroxy-19-norcorticosterone in patients with aldosterone-producing adenoma or idiopathic hyperaldosteronism.
abstract: Urinary excretion of 19-noraldosterone, 18. 19-dihydroxycorticosterone (18, 19(OH)2-B), 18-hydroxy-19-norcorticosterone (18-OH-19-nor-B), 18-hydroxycorticosterone (18-OH-B), 18-hydroxycortisol (18-OH-F) and aldosterone were measured in 25 patients with primary aldosteronism, 16 with an aldosterone-producing adenoma and 9 with idiopathic hyperaldosteronism. In patients with idiopathic hyperaldosteronism, urinary 19-noraldosterone (207 +/- 51 pmol/day), 18, 19(OH)2-B (21 +/- 4.2 nmol/day) and 18-OH-19-nor-B (879 +/- 213 pmol/day) levels were lower but not significantly different from 19-noraldosterone (263 +/- 56 pmol/day), 18, 19(OH)2-B (40 +/- 8.7 nmol/day) and 18-OH-19-nor-B (1322 +/- 267 pmol/day) seen in patients with aldosterone-producing adenoma. Urinary aldosterone did not differ significantly between patients with idiopathic hyperaldosteronism and those with aldosterone-producing adenoma. Both urinary 18-OH-B and 18-OH-F excretion were significantly higher in aldosterone-producing adenoma (39 +/- 5.2 nmol/day, 1660 +/- 318 nmol/day, respectively) compared with patients with idiopathic hyperaldosteronism (19 +/- 3.3 nmol/day, 541 +/- 93 nmol/day, respectively) (p less than 0.05). Though urinary 18-OH-F and 18-OH-B concentrations were useful markers, the mineralocorticoid steroids which we can only now measure, 19-noraldosterone, 18, 19(OH)2-B and 18-OH-19-nor-B, could not be used to distinguish the two subsets of primary aldosteronism.
authors.affiliation: Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: I
authors.initials: I
authors.lastname: Miyamori
authors.forename: K
authors.initials: K
authors.lastname: Iki
authors.forename: R
authors.initials: R
authors.lastname: Takeda
authors.forename: P
authors.initials: P
authors.lastname: Vecsei
mesh_terms: D015069:18-Hydroxycorticosterone / Q000031:analogs & derivatives* / Q000652:urine; D000236:Adenoma / Q000652:urine*; D000310:Adrenal Gland Neoplasms / Q000652:urine*; D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000031:analogs & derivatives* / Q000096:biosynthesis* / Q000652:urine; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000652:urine*; D008297:Male; D008875:Middle Aged; D012016:Reference Values
chemical_list: C051358:18-hydroxy-19-norcorticosterone; C051957:18,19-dihydroxycorticosterone; D000450:Aldosterone; D015069:18-Hydroxycorticosterone; C027514:19-noraldosterone